New Zealand and Mexico after the product is authorized in these national countries.

The World Health Corporation has recently identified osteoporosis as important health issue and also other major non-communicable diseases. Despite option of osteoporosis treatments for more than 10 years, patients with osteoporosis still encounter a substantial number of fractures. Out of around 9 million new osteoporotic fractures globally in 2000, 1.7 million were at the forearm, 1.6 million were at the hip, and 1.4 million were clinical fractures of the vertebrae in the backbone. About Amgen Amgen discovers, develops, delivers and manufactures innovative individual therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to understand the new science’s guarantee by bringing safe and effective medicines from lab, to manufacturing plant, to patient.ICON will also provide all assisting scientific services such as for example protocol design and development, project management, scientific monitoring, medical monitoring / pharmacovigilence, data management, biostatistics, pharmacokinetics and medical writing. ‘We are delighted that Bristol-Myers-Squibb has again selected ICON to bring higher operational efficiencies and top quality science to their drug development applications,’ commented Dr. Mario Rocci, President, ICON Development Solutions. ‘Both companies already have a very successful global partnership for phase II-IV clinical advancement and central laboratory solutions and we look forward to demonstrating the same worth and efficiencies to Bristol-Myers-Squibb’s early phase clinical applications.